Growth of Galenika and internationalization of business

Since becoming part of the Brazilian NC Group, Galenika has marked significant business growth and international expansion. In the period from 2018 to the end of 2022, Galenika doubled the volume of sales and exports, increased production by 22%, expanded the portfolio and registered as many as 146 products. With the support of the NC Group, and in partnership with EMS, the largest pharmaceutical company in Brazil, Galenika realized the transfer of technology for five generic medicines of the latest generation. In the following period, further investments in the amount of 35 million euros are planned in Serbia.

„Today, Galenika has 30 brands in leading positions in their categories in terms of market share in Serbia. We achieve constant growth on the Serbian market and in the region. Since operating within the NC Group, the company has doubled its sales and export levels and achieved great success in internationalization through a notable presence in international markets, thanks to the high quality of its products. In 2023, we plan to launch first products on the markets of Slovenia and Croatia, as well as further expansion on international markets. What is particularly significant is that over the next two years, in partnership with our sister company from Brazil - EMS, we plan to invest 35 million euros. Investments are aimed at further development in technology, production and warehouse capacities, all in accordance with business plans. In addition, by investing in further digitization of business, we plan to achieve an even greater degree of business efficiency’’, said Nenad Burazor, sales manager at Galenika.

You can read the full news on the Nedeljnik magazine website.